Alkermes vs Prestige Consumer Healthcare
Alkermes reported revenue of $1.5 billion in fiscal 2025, 1.4 times Prestige Consumer Healthcare's $1.1 billion in fiscal 2026. Alkermes' revenue fell 5.2% in its latest year, and Prestige Consumer Healthcare's fell 4.3%. Alkermes had an operating margin of 17.2%, against 28.4% at Prestige Consumer Healthcare. Free cash flow was $480 million at Alkermes and $246 million at Prestige Consumer Healthcare. Their fiscal years end in different months (December 31 and March 31), so the periods don't line up exactly.
Side by side
| Alkermes | Prestige Consumer Healthcare | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2026, Mar 31, 2026 |
| Revenue | $1.5B | $1.1B |
| Revenue growth | −5.2% | −4.3% |
| Revenue growth a year, last 5 years | 7.3% | 2.9% |
| Gross margin | 86.7% | 54.7% |
| Operating margin | 17.2% | 28.4% |
| Net margin | 16.4% | 17.5% |
| Free cash flow | $480M | $246M |
| Free cash flow margin | 32.5% | 22.6% |
| Return on capital | — | 8.2% |
| Net debt to EBITDA | — | 2.8x |
| Dividends and buybacks | $0M | $156M |
| Change in diluted share count | −0.3% | −2.7% |
| Last close | $45.90 | $42.98 |
| P/E at the last close | — | 13.3× |
| Insider trades, last 12 months | sold $10.0 million | sold $424,424 |
| Piotroski F-score | — | 5 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
AlkermesPrestige Consumer Healthcare
Operating margin
Percent of revenue
AlkermesPrestige Consumer Healthcare
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
AlkermesPrestige Consumer Healthcare
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Alkermes and Prestige Consumer Healthcare pages.